top of page

Free Biopharma Stock Content
Free biopharma stock updates and content regarding FDA catalyst updates, biotech stock news, and BiopharmIQ platform info.


Free Biopharma Daily Stock Updates - 04/12/22
$XBI $87.15 | -.019% Covid Updates $ Pipeline Updates $TPTX +0.6% Turning Point Therapeutics Announces Positive Topline Data by Blinded...
Apr 12, 2022


Free Biopharma Daily Stock Updates - 04/11/22
$XBI $87.32 | -3.34% Covid Updates $ Pipeline Updates $AGLE -6.5% Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3...
Apr 11, 2022
Biopharma Pulse - 4/4 - 4/8 Week in Review
As we have reached the end of the first full week of April, we review moves from smid-cap biopharma companies during this past week as...
Apr 8, 2022


Free Biopharma Daily Stock Updates - 04/08/22
$XBI $90.34 | +-2.3% Covid Updates $NVAX +1.9% Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax'...
Apr 8, 2022


Free Biopharma Daily Stock Updates - 04/07/22
$XBI $92.43 | -0.96% Covid Updates $ Pipeline Updates $MNOV +3.9% MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166...
Apr 7, 2022
American Association for Cancer Research (AACR) Annual Meeting 2022
Summary The American Association for Cancer Research (AACR) annual meeting takes place from April 8-13, 2022 online and in New Orleans...
Apr 7, 2022
CHRS - Bull Thesis
CHRS is a very unusual small-cap biopharma stock because it started as. and still remains in part, a biosimilar company. A biosimilar is...
Apr 7, 2022


Free Biopharma Daily Stock Updates - 04/06/22
$XBI $93.33 | +0.086% Covid Updates $ Pipeline Updates $SPRO -4.1% Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data...
Apr 6, 2022
GBT - Bull Thesis
BULL THESIS GBT overall corporate and executive summary Cash of $735M in Q4 ‘21, almost doubled in last quarter A little over 2 years of...
Apr 6, 2022


Free Biopharma Daily Stock Updates - 04/05/22
$XBI $93.25 | -2.96% Covid Updates $TNXP -4.9% Tonix Pharmaceuticals Announces Extension of Sponsored Research Agreement with Kansas...
Apr 5, 2022


Free Biopharma Daily Stock Updates - 04/04/22
$XBI $96.09 | +3.0% Covid Updates $ALGS +4.0% Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral...
Apr 4, 2022


Free Biopharma Daily Stock Updates - 04/01/22
$XBI $93.26 | +3.76% Pipeline Updates $CYTK Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of...
Apr 2, 2022
Biopharma Pulse - 3/28 - 4/1 Week in Review
As March concluded this week, we review moves from smid-cap biopharma companies during this past week as well as March as a whole. See...
Apr 1, 2022


Free Biopharma Daily Stock Updates - 03/31/22
$XBI $89.88 | -0.88% Covid Updates $SRNE -1.7% Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib...
Mar 31, 2022


Free Biopharma Daily Stock Updates - 03/30/22
$XBI $90.68 | -3.07% Covid Updates $CYDY +0.8% CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19...
Mar 30, 2022


Free Biopharma Daily Stock Updates - 03/29/22
$XBI $93.55 | +4.28% Covid Updates $BNTX +3.6% & $PFE -1.0% Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for...
Mar 29, 2022


Free Biopharma Daily Stock Updates - 03/28/22
$XBI $89.71 | +0.1% Covid Updates $ Pipeline Updates $NBIX -0.1% Neurocrine Biosciences Announces Regulatory Approval of Dysval®...
Mar 28, 2022


Free Biopharma Daily Stock Updates - 03/25/22
$XBI $89.62 | -2.34% Covid Updates $VIR US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to...
Mar 26, 2022
Biopharma Pulse - 3/21 - 3/25 Week in Review
As we near the end of March, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and...
Mar 25, 2022


Free Biopharma Daily Stock Updates - 03/24/22
$XBI $91.77 | +2.13% Covid Updates $AZN +2.6% Evusheld long-acting antibody combination recommended for approval in the EU for the...
Mar 24, 2022
Jump start your biotech due diligence
Our platform helps you uncover your next biotech investment opportunity
bottom of page
